MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is stepping into one of biotech’s most important global spotlights, with its top executive set to present the company’s gene therapy strategy at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco later this month.
Chairman, Chief Executive Officer and co-founder Dr. Shankar Musunuri will deliver Ocugen’s formal presentation on Thursday, January 15, as the company looks to showcase a pipeline that management says could reshape treatment for inherited eye diseases and accelerate its path to regulatory filings.
The J.P. Morgan Healthcare Conference, running January 12 through January 15 at The Westin St. Francis, is widely regarded as the opening bell for the global health care investment calendar. For emerging biotechnology companies, it is one of the few venues where scientific progress, capital markets and strategic partnerships converge in one place.
Ocugen plans to use that platform to highlight its modifier gene therapy platform and provide updates on clinical development programs that are moving closer to regulatory review. The company has laid out a goal of filing three biologics license applications over the next two years, including a rolling BLA this year for OCU400, its gene therapy candidate for retinitis pigmentosa.
Musunuri said the company’s growing presence at the JPM conference reflects how its science and development strategy have matured, as Ocugen pushes toward what it describes as a catalyst-rich 2026. Beyond the formal presentation, Ocugen’s executive team will spend the week meeting with potential partners and investors to outline its business strategy and commercialization plans.
Dr. Musunuri’s presentation is scheduled for 9:45 a.m. to 10:25 a.m. Pacific time on January 15 in the Colonial Room on the Mezzanine level of the conference venue.
For investors tracking the crowded but fast-moving gene therapy space, Ocugen’s appearance at JPM is more than a speaking slot. It is a test of whether the company can convert scientific ambition into credible timelines and partnerships as it moves closer to the regulatory and commercial phases of its development cycle.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.